Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Galunisertib (Primary) ; Lomustine
- Indications Glioma
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 06 Jan 2017 Planned End Date changed from 1 Sep 2016 to 1 Oct 2018.
- 04 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016 as per ClinicalTrials.gov record.
- 13 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.